Xbrane's Ranibizumab Biosimilar Shows Equivalent PK and Tolerability to Lucentis
October 4th 2018Swedish biotechnology company Xbrane Biopharma today announced that its ranibizumab biosimilar, referencing Lucentis, demonstrated an equivalent pharmacokinetic (PK) profile and equivalent tolerability to its reference in an in vivo study.
FDA Takes Steps Against Citizen Petitions Used to Delay Generic or Biosimilar Competition
October 4th 2018The FDA this week announced revised draft guidance that it says will help ensure that citizen petitions cannot be used by brand-name drug makers to delay the market entry of generics or biosimilars of branded products.
Health Canada Approves Trastuzumab for Subcutaneous Administration
October 1st 2018Health Canada has approved a formulation of Roche’s originator trastuzumab, Herceptin, that is intended for subcutaneous administration. The drug, indicated to treat HER2-positive cancers, can be administered in 2 to 5 minutes (versus an average of 90 minutes for intravenous administration).
Literature Review Finds Insufficient Evidence for Biosimilar Nocebo Effect
October 1st 2018In explaining why some patients who switch to biosimilars from reference biologics discontinue their therapy at a higher rate than those who remain on a therapy without interruption, some authors have referenced the so-called “nocebo” effect. This effect, whereby a patient experiences disease worsening or adverse events due to negative beliefs about a drug, has been controversial, however, and not all clinicians agree that the effect is to blame for differences in discontinuation.
EU Authorizes Second Pegfilgrastim Biosimilar, Pelgraz
September 26th 2018The European Union (EU) today authorized its second pegfilgrastim biosimilar, referenced on Neulasta. The product, to be sold as Pelgraz, is indicated to reduce the duration of neutropenia, as well as the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy.
BEVZ92 Highly Similar to Reference Bevacizumab in PK, Efficacy, Immunogenicity, and Safety
September 25th 2018Notably, the study was conducted in patients with cancer, rather than in a healthy population, to generate evidence of pharmacokinetic (PK) equivalence in a scenario that reflects how the biosimilar would be used in clinical practice.
CBO Says CREATES Act Would Reduce Federal Spending on Prescription Drugs
September 24th 2018In its report, the Congressional Budget Office (CBO) notes that it “expects that the bill’s provisions would allow generic drugs (including biosimilar versions of biologics) to enter the market earlier, on average, than they would under current law.” Additionally, CBO said that enacting the legislation would reduce federal spending on prescription drugs.
3 Key Considerations for Implementing Biosimilars in Health Systems
September 24th 2018It’s no secret that hospitals and health systems continue to face pressure to improve patient outcomes while managing the total cost of care. Now, biosimilars present an opportunity to address both needs. They are clinically equivalent to reference biologic products and offer potentially significant savings. Yet many hospitals struggle to change their formularies and physician preferences for these medications.
UK Health System Wins the Right to Treat AMD With Bevacizumab
September 24th 2018A United Kingdom court has ruled in favor of the National Health Service, allowing the health system to provide intravitreal injections of the anti–vascular endothelial growth factor agent bevacizumab to patients with age-related macular degeneration (AMD).
Iranian Biosimilar Rituximab Noninferior to Its Reference in Treating CLL
September 24th 2018A recently published study between the biosimilar and the reference rituximab, MabThera, demonstrated that the biosimilar was noninferior to the reference in terms of both efficacy and safety in treating chronic lymphocytic leukemia (CLL).
Filgrastim May Provide an Alternative to Discontinuing Clozapine Therapy
September 23rd 2018The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited. A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption.
Sandoz, Cinfa, Mylan All Receive CHMP Recommendations for Pegfilgrastim Biosimilars
September 21st 2018Today, Sandoz, Cinfa Biotech, and Mylan all revealed that they have received positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for proposed pegfilgrastim biosimilars referencing Neulasta.
In Brazil, Government and Industry Partner to Develop Biosimilars
September 21st 2018Brazil benefits from a program, known as the Partnership for Productive Development, that brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of high-cost biologics that account for approximately half of annual drug spending.